Abstract Background Post-menopausal women have an enhanced risk of developing cardiovascular disease and disturbances of cardiac rhythm, generally attributed to declining oestrogen levels during menopause. In an animal model that mimics menopause, the long-term withdrawal of oestrogen dysregulated Ca2+ signalling and increased the formation of a pro-arrhythmic substrate. Selective targeting of the membrane bound G-protein coupled oestrogen receptor 1 (GPER) eliminated such arrhythmogenic activity associated with the loss of oestrogen. Purpose We aim to assess the “cardioprotective” role of GPER in response to oestrogen withdrawal. Methods Ovariectomy (OVx) or sham surgeries were conducted on female guinea pigs. Left ventricular cardiomyocytes were isolated 150-days post-operatively for experimental use. GPER expression was quantified by western blot. Myocytes were incubated in solutions containing GPER agonist G-1 for >2h before recording some electrophysiological and Ca2+ regulatory parameters. Results GPER expression was 32% higher in OVx. OVx cardiomyocytes had prolonged action potential duration (APD) compared with sham and in the presence of G-1, APD90 shortened by 12% and 22% in sham and OVx, respectively. G-1 reduced early after depolarisation (EAD) formation by >99% in OVx. OVx cells had larger sarcoplasmic reticulum (SR) Ca2+ content (by 13%), compared with sham. While G-1 had little effect on SR content, it reduced Ca2+ transient amplitude (by 40%), SR fractional release (by 11%) and sarcomere shortening (by 29%) in OVx cells. The frequency of occurrence of spontaneous Ca2+ waves evoked by periods of rapid stimulation reduced by 40% and wave-free survival time prolonged in OVx cells incubated with G-1. Conclusions In the hearts of an animal species whose electrophysiology and intracellular Ca2+ regulation is akin to humans, we show that following oestrogen deficiency, GPER expression increased and its activation induces negative inotropic responses in cardiomyocytes. It limits the adverse changes to Ca2+ signalling and induces anti-arrhythmogenic behaviours in OVx. Funding Acknowledgement Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): British Heart Foundation